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change in weight measured by BMI and raw weight in elderly T2DM patients in a 
real-world setting. The likelihood of weight loss in OAD users was somewhat consis-
tent with the literature.
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OBJECTIVES: Renal insufﬁciency (RI), a common complication of type 2 diabetes 
mellitus (T2DM), is associated with increased morbidity, mortality and costs. Early 
and accurate detection of RI among patients with T2DM is essential in delaying or 
reducing these outcomes. Consensus guidelines advocate the use of estimated glomeru-
lar ﬁltration rate (eGFR) to assess renal function. The objective of this retrospective 
database analysis was to evaluate the prevalence of RI in a commercially-insured 
population with T2DM using ICD-9-CM codes and laboratory data from a large, 
national US health plan. METHODS: The study sample consisted of commercially-
insured health plan members ≥18 years of age with evidence of T2DM from 1/1/06–
12/31/07 and continuous enrollment for 12 months before and after identiﬁcation of 
T2DM. The prevalence of RI was determined by physician diagnosis using ICD-9-CM 
codes (“physician-diagnosed”), and eGFR calculation using serum creatinine (SCr), 
age and gender (“eGFR-diagnosed”). Approximately 26.8% of members had labora-
tory data (≥1 SCr value) after identiﬁcation; physician-diagnosed and eGFR-diagnosed 
RI prevalences were identiﬁed in this subset. RI was identiﬁed using the National 
Kidney Foundation (NKF) 5-stage classiﬁcation system and deﬁned as ≥ stage 2, or 
an eGFR of £89 ml/min. Comparisons between cohorts were made using chi-squares. 
RESULTS: Among over 13.7 million commercially-insured members within the data-
base, 664,619 (4.8%) had evidence of T2DM. The sample included 259,295 members 
after applying continuous enrollment and other study criteria, of which 20,914 (9.2%) 
had evidence of physician-diagnosed RI. Among the subset with laboratory data avail-
able (n = 69,439), 6,795 (9.8%) had physician-diagnosed RI while 17,981 (25.9%) 
had evidence of eGFR-diagnosed RI (p < 0.001). CONCLUSIONS: The prevalence of 
RI within a commercially-insured population with T2DM was signiﬁcantly higher 
using eGFR, the recommended method of estimating RI, than physician diagnosis of 
RI. It is likely that RI in the commercially-insured is under-estimated using diagnosis 
codes in claims data.
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OBJECTIVES: The objective of this study was to compare glycaemic control and 
insulin utilisation in insulin naïve patients with type 2 diabetes (T2D) after initiation 
on biphasic insulin aspart 30 (BIAsp) or biphasic human insulin 30 (BHI) METHODS: 
A retrospective cohort study was conducted using the IMS Disease Analyzer a UK 
primary care database. Study inclusion required subjects to be insulin naïve with at 
least one prescription for an oral anti-diabetic agent (proxy for T2D diagnosis), 12 
months history and follow up and treatment with either BIAsp or BHI. Patients with 
a diagnosis of type 1 diabetes were excluded. Glycemic control (HbA1c) was compared 
at baseline (-6 to 0 months) and at follow-up (+6 to 12 months). Average daily insulin 
dose (ADD) was compared at follow-up. Effect of age and sex as covariates on the 
difference in HbA1c and ADD between BIAsp and BHI was controlled for using 
ANOVA. RESULTS: Analyses were conducted on 630 BIAsp and 751 BHI patients 
on whom full data was available. The mean age for BIAsp patients was 61.6 years 
(59.7% men). For BHI, the mean age was 64.4 (51.9% men). From baseline to follow-
up, the mean HbA1c for BIAsp dropped from 9.95% to 8.16% (change = 1.79%) 
and for BHI the HbA1c dropped from 10.34% to 8.62% (change = 1.72%). The 
HbA1c difference was borderline signiﬁcant (p = 0.07). The ADD of BIAsp was 46.97 
insulin units whereas the BHI ADD was 63.28 IU (p < 0.01). CONCLUSIONS: In 
this large retrospective analysis in insulin naïve patients initiated on pre-mixed insulin 
there was a trend towards better glycaemic control for users of BIAp compared to 
BHI. Moreover, BIAsp was associated with a clinically relevant and statistically sig-
niﬁcantly lower ADD compared to BHI (p < 0.01). This has important implications 
for patient management and control of UK NHS costs.
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OBJECTIVES: As decision-makers and the citizens they serve demand stronger evi-
dence to support coverage, prioritization, and pricing, the need for relative effective-
ness research has come to the fore. Whilst it is well known and documented that 
differences in costing structures, practise patters and unit costs can lead to differences 
in cost effectiveness estimates for any given clinical effect, less is known about the 
heterogeneity of treatments and their utilization to demonstrate Relative Effectiveness 
(RE) among EU countries. This study investigated differences in treatment availability 
and utilization using recommendations from HTA agencies as a proxy. METHODS: 
HTA reports were searched using 7 European HTA agencies websites (i.e., NICE, 
SMC, IQWIG, HAS, CAHTA, CVZ, TLV with the following keywords: pioglitazone, 
rosiglitazone, sitagliptin, vildagliptin, exenatide, glargine, detemir, aspart, glulisine 
and lispro. Recommendation was classiﬁed in three categories: recommended, 
restricted recommended, and not recommended in relation to indication based on 
marketing authorisation. RESULTS: No HTA agency had similar recommendations 
for all treatments. IQWIG recommended none of the products assessed (8), while 
Sweden recommended 86% of the products assessed (7). NICE, SMC, HAS, CAHTA 
and CVZ assessed 18, 8, 18, 15, and 10 products, recommending 22%, 50%, 56%, 
13% and 0%, restricting 78%, 50%, 22%, 47% and 50% respectively. CONCLU-
SIONS: Large differences in recommendation of products among EU countries exist. 
As diabetes is a well established disease area, one would expect a more uniform 
armamentarium of recommended treatments. In light of the RE management plans, 
this research questions whether it is possible and desirable to develop a uniﬁed 
approach. Future research should focus on standardization of methods and address 
questions about acceptable methodology and its limitations.
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OBJECTIVES: The objective of the study was to compare real-life glycaemic control, 
insulin utilisation and body weight in patients with type 2 diabetes initiated on insulin 
detemir (IDet) or insulin glargine (IGlar) and to discuss the results against treatment 
guidelines. METHODS: Patients with a history of oral anti-diabetic use starting treat-
ment with IDet or IGlar from 2004 through 2006 were included in a retrospective 
cohort study using the Dutch PHARMO data network. Glycaemic control (HbA1c < 
7%) and daily insulin dose during unchanged insulin treatment up to 1 year of follow-
up were compared between IDet and IGlar users using multivariate regression analysis 
adjusted for age, gender, propensity scores, baseline HbA1c and basal-bolus therapy. 
The observed results are discussed in context of European diabetes guidelines. 
RESULTS: A similar (p = 0.44) drop in HbA1c (from 8.6% to 7.5%) was observed 
for both IDet (n = 199) and IGlar (n = 479). Few patients were at goal at baseline 
(15.6% with IDet and 12.1% with IGlar). A similar proportion were at goal at follow-
up (38.7% with IDet and 33.4% with IGlar) (adjusted OR 1.06; 95% CI 0.74:1.53). 
The average daily dose was similar at 29 IU/day (adjusted mean difference 0.2; 95% 
CI -2.9:3.2). Median weight loss was 1 kg among IDet users and 0 kg among IGlar 
users, but this was not statistically tested due to low patient numbers. CONCLU-
SIONS: There was no signiﬁcant difference between users of IDet and IGlar with 
respect to glycaemic control and insulin dose in a real-life setting in the The Nether-
lands. However, compared with treatment guidelines, the results showed few patients 
treated to target, which may indicate that basal insulin analogues are not titrated 
intensive enough or that rapid-acting insulin should be added to improve glycaemic 
control.
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OBJECTIVES: Studies suggest that premixed insulin analogues may improve the 
balance between glycaemic control and hypoglycaemia compared with human pre-
mixed insulin in type 2 diabetes (T2D) patients. This study aimed to observe prescrip-
tion patterns of premixed insulin analogues compared to human premixed insulin 
among T2D patients. METHODS: Data for T2D patients starting premixed insulin 
in the period 2004–2006 were extracted from the Dutch PHARMO database. Patients 
were categorized into insulin naïve and prior insulin users. The proportion of patients 
changing treatment (discontinuing, adding fast-acting insulin or switching treatment) 
within one year was determined. Data was analyzed using Chi-Square tests for cate-
gorical data and t-tests for continuous data. RESULTS: The study included 3530 
patients initiated on premixed insulin, of which 2324 (65.8%) were insulin naïve. 
Overall, 2134 (60.5%) started on analogues; the proportion of prescribed analogue 
insulin was greater among prior insulin users (812 of 1206 = 67.3%) vs. naïve users 
(1322 of 2324 = 56.9%). Patient characteristics did not differ between human insulin 
and analogue users, except from baseline HbA1c: in the group of prior users (1206 / 
34.2%), a signiﬁcant difference in baseline HbA1c was observed between those using 
human premixed insulin (8.5%) and premixed analogue (8.0%, p < 0.001). Within 
one year, 44.1% of human premixed users and 33.5% of premixed analogue users 
changed treatment. Among human premixed users 20.1% discontinued treatment (230 
days), 6.5% added fast-acting insulin to their therapy (114 days), and 17.6% switched 
treatment (143 days); among premixed analogue users 14.9% discontinued treatment 
(245 days), 5.8% added fast-acting insulin (137 days), and 12.9% switched treatment 
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(155 days). CONCLUSIONS: Premixed insulin analogues were more frequently pre-
scribed by Dutch physicians than human premixed insulin. Users of premixed insulin 
analogues neither discontinued nor switched therapy as frequently as human premixed 
users, suggesting that premixed analogues gave a more sustained and satisfactory 
result.
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OBJECTIVES: To apply a risk assessment algorithm to a national US population 
sample (i) to determine the prevalence of at-risk pre-diabetic and undiagnosed diabetic 
participants and (ii) to validate the role of the risk factors included in the scoring 
algorithm in the prediction of diagnosed type 2 diabetes. METHODS: Data from the 
2009 US National Health and Wellness Survey (NHWS) were used to apply a modiﬁed 
version of a recently developed scoring algorithm/prediction model to identify patients 
at-risk for screening for pre-diabetes and undiagnosed diabetes. The algorithm com-
bines six risk factors to generate total risk scores: age, gender, family history of 
hypertension, high blood pressure, obesity, and physical activity. Estimates of the 
national prevalence of those at risk together with key health status attributes were 
generated. RESULTS: Among those 18 years of age and over in the NHWS sample 
(N = 74,474) without a conﬁrmed diagnosis of diabetes, 27.3% of participants were 
estimated to be at elevated risk for diabetes and a further 16.5% for pre-diabetes. 
Among those with a conﬁrmed diagnosis of diabetes (excluding persons with type 1 
diabetes), 73.6% were conﬁrmed by the scoring algorithm with a further 13.8% 
meeting pre-diabetic criteria. Overall, 10.0% had a conﬁrmed type 2 diabetes diag-
nosis. The ﬁtted prediction model indicated the following variables were strongest risk 
factors in the NHWS sample: i) age 60 years and over (odds ratio 6.94); ii) morbid 
obesity (odds ratio 6.11); iii) a family history of diabetes (odds ratio 4.79); and (iv) 
being obese (odds ratio 3.04). All variables signiﬁcant at the 1% level. The sensitivity 
was 23.2%, speciﬁcity 97.8%, positive predictive value 57.3% and negative predictive 
value 91.0%, with area under the ROC curve of 0.847. CONCLUSIONS: This study 
provides strong support for the new scoring algorithm to identify both pre-diabetic 
and diabetic at-risk populations.
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OBJECTIVES: Results of intervention studies in patients with type 2 diabetes have 
led to concerns about the safety of aiming for normal blood glucose concentrations. 
We assessed survival as a function of HbA1c in people with type 2 diabetes. 
METHODS: Two cohorts of patients aged 40 years and older with type 2 diabetes 
were generated from the THIN database of UK general practice records from 1986 
to 2008. Those with diabetes secondary to other causes were excluded. We identiﬁed 
37,626 and 22,769 patients commenced on metformin or sulphonylurea monotherapy 
respectively; 24,784 intensiﬁed from oral monotherapy to combination therapy with 
oral blood-glucose lowering agents; and 15,855 changed to regimens that included 
insulin. All-cause mortality was the primary outcome. Age, sex, smoking status, 
cholesterol, cardiovascular risk, and general morbidity were identiﬁed as important 
confounding factors, and Cox survival models were adjusted for these factors accord-
ingly. RESULTS: Compared to the HbA1c response category 7.0 to ≤7.5, those 
achieving the tightest glycaemic control (mean post-index HbA1c < 6.1%) had a 
substantially elevated adjusted hazard ratio for all-cause mortality (HR = 1.52 [95%CI 
1.39 to 1.66]), as did those with the poorest glycaemic control (HbA1c response > 
10%, HR 1.45 [1.30 to 1.63]). A ‘U-shaped’ association between glycaemic control 
and survival emerged in all treatment cohorts for which the adjusted HR in those 
achieving tightest glycaemic control (cf. referent) ranged from 1.44 (1.20 to 1.72) for 
metformin monotherapy to 2.61 [2.05 to 3.32] for the insulin-treated cohort. CON-
CLUSIONS: Low and high mean HbA1c values were associated with increased all-
cause mortality corroborating the ﬁndings of the ACCORD trial. Diabetes guidelines 
and current health economic models may need revision to reﬂect the safety implica-
tions of very tight glycaemic control in Type 2 diabetes.
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OBJECTIVES: Patients with type 2 diabetes are at increased risk for cardiovascular 
(CV) events. Whether agents that reduce hyperglycemia increase, decrease, or have no 
effect on CV outcomes is important. Comparative data among newer agents are 
limited. The study objective was to assess the relative incidence rate of CV events 
among patients prescribed exenatide, a GLP-1 receptor agonist, versus thiazolidinedio-
nes (TZDs). METHODS: Intent-to-treat analyses utilizing the LifeLink™ health plan 
claims database included patients initiating a new prescription for exenatide or a TZD 
between June 1, 2005, and March 31, 2009, and had no evidence of exenatide or 
TZD use in the prior 9 months. Patients were assigned to exenatide or TZD groups 
based on the ﬁrst new prescription. For the primary analysis, patients were followed 
until one of the following occurred: CV event (acute myocardial infarction, stroke, or 
coronary revascularization procedure), insurance disenrollment, or study end. Patient 
outcomes, adjusted for differences in clinical and demographic characteristics, were 
compared using person-time (Poisson regression) analyses. A secondary analysis of 
hospitalization rates was conducted. RESULTS: A total of 23,972 and 66,860 patients 
were assigned to exenatide and TZD therapies, respectively. Mean (SD) ages were 52 
(± 9.3) years (exenatide-treated) and 54 (± 10.8) years (TZD-treated). 41.9% of 
exenatide-treated patients and 53.9% of TZD-treated patients were male. Exenatide-
treated patients were more likely to have hyperlipidemia (63.4% vs. 55.0%) and 
hypertension (62.4% vs. 57.1%). Exenatide-treated patients were 17% less likely than 
TZD-treated patients to have a CV event (HR = 0.83; CI, 0.77–0.89; P < 0.0001). 
The exenatide group had signiﬁcantly lower rates of CV-related hospitalization (RR 
= 0.77; P < 0.0001). CONCLUSIONS: In this analysis of glucose-lowering therapies, 
exenatide treatment was associated with a lower risk of CV-related events compared 
to TZD treatment.
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OBJECTIVES: To study predictors of statin use in overweight and obese adults and 
consistency with current 2004 American Diabetes Association (ADA) guidelines. 
METHODS: A retrospective cross-sectional analysis of National Ambulatory Medical 
Care Survey (NAMCS) and outpatient part of the National Hospital Ambulatory 
Medical Care Survey (NHAMCS) of 2005–2007 was conducted among overweight 
and obese adults aged 18 to 64 years. Statin prescription (received or not) was the 
outcome measure. Descriptive statistics and multivariate logistic regression were 
carried using SAS9.2 to determine predictors of receiving statin prescriptions. The 
multivariate model was stratiﬁed based on age: Model1¬¬ (18 to 40years) and Model2 
(41 to 64years), as a signiﬁcant interaction was found between diabetes and age (chunk 
test p = 4.3729e-8). RESULTS: A total of 3141.387 million visits were examined, 
94.176 (2.99%) with a statin prescription. Diabetics were more likely to receive a 
statin prescription compared to nondiabetics [Model1: Odds Ratio (O.R.) 4.12 
(95%Conﬁdence Interval (C.I.): 2.77–6.12, p < 0.0001); Model2: O.R. 2.69 (95%C.I: 
2.21–3.27, p < 0.0001)]. Females were less likely to get statin prescription compared 
to males [Model1: O.R.0.52 (C.I. 0.42–0.63 p < 0.0001) Model2: O.R.0.68 (C.I. 
0.59–0.78 p < 0.0001)]. Specialists were more likely to prescribe statin compared to 
generalists [Model1: O.R. 1.44 (C.I:1.31–1.84, p = 0.0033); Model2: O.R. 1.61 (C.I: 
1.35–1.91, p < 0.0001)]. Other signiﬁcant predictors included hypertension (p1 = 
0.0037; p2 < 0.0001), hyperlipidemia (p1 < 0.0001; p2 < 0.0001), congestive heart 
failure (p1 = 0.0044; p2 < 0.0004) and counseling (p1 = 0.0011, p2 < 0.0001). Race 
and payment type were not signiﬁcantly associated. CONCLUSIONS: Diabetics were 
more likely to receive statin prescriptions compared to nondiabetics, consistent with 
ADA recommendations. Further research is needed to ensure achievement of target 
cholesterol levels in this high risk population.
DIABETES/ENDOCRINE DISORDERS – Cost Studies
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OBJECTIVES: A new dipeptidyl peptidase-4 inhibitor, saxagliptin, has been recently 
approved for the T2D treatment. This study evaluates the budget impact of the intro-
duction of saxagliptin to the Brazilian Private Healthcare System (PHS). METHODS: 
A model was developed to estimate the annual cost of T2D treatment per patient of 
the population potentially impacted by the introduction of saxagliptin to the PHS. 
The analysis also estimates the economic impact to the system of all oral anti-diabetic 
drugs (OADs) for 3 consecutive years. Target population (T2D patients on OADs and 
HbA1c uncontrolled) and patient distribution across therapeutic options are based on 
epidemiological and pharmacoepidemiological data, and clinical specialist interviews. 
Pharmaceutical direct costs are based on factory price (FP) and Deﬁned Daily Dose 
(DDD). We assumed saxagliptin FP to be 115.3% of sitagliptin FP. Univariate Deter-
ministic sensitivity analysis is conducted to determine the impact of parameters on 
results. RESULTS: The growth in population and prevalence increased the target 
population throughout the analysis. The prevalence estimate in year 1 was 328,218 
and increased to 349,212 in year 3. The growth also impacted total costs in scenario 
